Despite noting the high unmet need in Duchenne muscular dystrophy, the FDA panel concluded that trial data lacked substantial evidence of the therapy's effectiveness.
A dose-escalation study in 24 healthy adults showed that an 810mL infusion produced results comparable to fresh frozen plasma without significant safety signals. The Food and Drug Administration (FDA) ...